Trials / Completed
CompletedNCT04038333
Financing Strategies of Influenza Vaccination in China
Influenza Vaccination Among Three Recommended Groups in China: Economic Burden, Vaccine Hesitancy, Discrete Choice Experiment, Immunization Records, Willingness to Pay and Financing Strategies
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 13,542 (actual)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- Accepted
Summary
This trial focuses on influenza vaccination among three recommended groups in China. Data concerning the economic burden of influenza-like illness (ILI), vaccine hesitancy, discrete choice experiment, immunization records and willingness to pay for vaccines will be collected via questionnaires, and the financing strategies of influenza vaccines in China will be further analyzed. Besides, the knowledge, attitude/belief and practice (KAP) of medical staff will also be asked in a supplementary questionnaire.
Detailed description
This trial focuses on influenza vaccination among three recommended groups in China, including children (aged between 6 to 59 months), the elderly (aged 60 years old or above), and adult patients with chronic diseases (aged below 60 years old). The questionnaires will collect data on the economic burden of influenza-like illness (ILI), vaccine hesitancy, discrete choice experiment, immunization records and willingness to pay for vaccines, and the financing strategies of influenza vaccines in China will be further analyzed accordingly. Besides the three recommended groups, vaccination and health care personnel will also be asked about their knowledge, attitude/belief and practice (KAP) in a supplementary questionnaire.
Conditions
- Influenza Vaccines
- Influenza, Human
- Cost of Illness
- Health Knowledge, Attitudes, Practice
- Immunization Programs
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | This is an observational study without any interventions. |
Timeline
- Start date
- 2019-08-01
- Primary completion
- 2019-10-30
- Completion
- 2021-03-10
- First posted
- 2019-07-30
- Last updated
- 2022-01-24
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04038333. Inclusion in this directory is not an endorsement.